<p>诺瓦瓦克斯（NasdaqGS:NVAX）最近报告了 2025 年第一季度的显著财务好转，显示出可观的收入增长和净利润改善。与武田的合作协议的修订提供了在疫苗开发方面更大的灵活性，而查尔斯·牛顿的新董事会任命增强了公司在医疗保健领域的战略领导力。在过去一周，诺瓦瓦克斯的股价上涨了 13%，略微超过了整体市场 5% 的涨幅，表明投资者对这些发展的乐观情绪。这些因素可能进一步推动了股票的上涨，符合积极的市场趋势。</p>
<p>我们认为诺瓦瓦克斯有 5 个可能的警示信号（其中 2 个比较不愉快），你应该了解。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9d1b1b15-a1f8-402a-96c1-a72a7b04b6c4/chart/earnings-per-share-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9d1b1b15-a1f8-402a-96c1-a72a7b04b6c4/chart/earnings-per-share-growth"/></p>
<p>截至 2025 年 5 月的 NasdaqGS:NVAX 每股收益增长</p>
<p>揭示 16 家在 COVID 后生存并繁荣的公司，它们具备生存特朗普关税的正确要素。</p>
<p>诺瓦瓦克斯最近的组织变动和与武田的合作修订可能会增强公司的未来收入来源和运营灵活性。在这些公告后，股价上涨 13% 表明投资者信心上升。然而，从长远来看，考虑到股价变动和股息，公司总回报在过去一年中下降了 48.27%。这一时期突显了诺瓦瓦克斯面临的重大波动性和挑战，强调了持续战略调整的必要性。</p>
<p>与整体市场上涨 11.9% 和美国生物技术行业在过去一年中下降 14.2% 相比，诺瓦瓦克斯的股票表现显著不佳。分析师预测，未来三年收入预计将每年下降 31%，而收益预计将每年下降 44.3%。最近的公告可能有助于缓解部分下降，通过潜在扩大市场机会和通过合作伙伴关系增强盈利能力，但对合作伙伴执行的持续依赖仍然是一个主要风险。</p>
<p>分析师设定的目标价为 15.17 美元，显著高于当前股价 6.42 美元。这意味着如果诺瓦瓦克斯能够满足未来预期，潜在增长空间巨大。公司通过合作伙伴关系和成本优化的持续适应是影响其收入和收益增长前景的关键因素，使其更接近分析师的估值预期。</p>
<p>通过我们的报告获取诺瓦瓦克斯的前景和预期表现的见解。</p>
<p><em>这篇文章由 Simply Wall St 撰写，性质为一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也不考虑你的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<p>如果你想交易诺瓦瓦克斯，请在专业人士信任的最低成本平台 Interactive Brokers 开设账户。</p>
<p>IBKR 在 200 多个国家和地区拥有客户，并可访问 160 个市场，让你可以通过一个集成账户交易股票、期权、期货、外汇、债券和基金。</p>
<p>享受无隐藏费用、无账户最低限额，外汇转换率低至 0.03%，远优于大多数经纪商提供的服务。</p>
<p>赞助内容</p>

诺瓦瓦克斯医药

<p>诺瓦瓦克斯（NasdaqGS:NVAX）在 2025 年第一季度报告了显著的财务好转，收入增长显著，净收入改善。该公司修订了与武田的合作协议，增强了疫苗开发的灵活性。诺瓦瓦克斯的股价上涨了 13%，超过了大盘 5% 的涨幅，反映了投资者的乐观情绪。然而，该公司面临挑战，包括过去一年总回报下降 48.27% 以及预计收入和盈利下降。分析师设定的目标价为 15.17 美元，表明如果诺瓦瓦克斯能够满足预期，仍有增长潜力</p>

<p>Novavax (NasdaqGS:NVAX) recently reported a significant financial turnaround for Q1 2025, demonstrating substantial revenue growth and net income improvements. The amending of its collaboration agreement with Takeda offers increased flexibility in vaccine development, while the new board appointment of Charles Newton enhances the company's strategic leadership in healthcare. Over the last week, Novavax's shares rose by 13%, slightly exceeding the broader market's 5% increase, indicating investor optimism around these developments. These factors likely reinforced the stock's upward movement, in line with positive market trends.</p>
<div class="lb-trans"><p>诺瓦瓦克斯（NasdaqGS:NVAX）最近报告了 2025 年第一季度的显著财务好转，显示出可观的收入增长和净利润改善。与武田的合作协议的修订提供了在疫苗开发方面更大的灵活性，而查尔斯·牛顿的新董事会任命增强了公司在医疗保健领域的战略领导力。在过去一周，诺瓦瓦克斯的股价上涨了 13%，略微超过了整体市场 5% 的涨幅，表明投资者对这些发展的乐观情绪。这些因素可能进一步推动了股票的上涨，符合积极的市场趋势。</p>
</div><p>Novavax has 5 possible red flags (and 2 which are a bit unpleasant) we think you should know about.</p>
<div class="lb-trans"><p>我们认为诺瓦瓦克斯有 5 个可能的警示信号（其中 2 个比较不愉快），你应该了解。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9d1b1b15-a1f8-402a-96c1-a72a7b04b6c4/chart/earnings-per-share-growth" alt="" original-src="https://images.simplywall.st/company/9d1b1b15-a1f8-402a-96c1-a72a7b04b6c4/chart/earnings-per-share-growth"/></p>
<p>NasdaqGS:NVAX Earnings Per Share Growth as at May 2025</p>
<div class="lb-trans"><p>截至 2025 年 5 月的 NasdaqGS:NVAX 每股收益增长</p>
</div><p>Uncover 16 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.</p>
<div class="lb-trans"><p>揭示 16 家在 COVID 后生存并繁荣的公司，它们具备生存特朗普关税的正确要素。</p>
</div><p>The recent organizational changes and amendments in Novavax's collaboration with Takeda could potentially bolster the company's future revenue streams and operational flexibility. The increase in share price by 13% following these announcements is indicative of rising investor confidence. However, over the longer term, the company's total return, considering both share price movement and dividends, saw a 48.27% decline over the past year. This period highlights significant volatility and challenges faced by Novavax, underscoring the need for continued strategic adjustments.</p>
<div class="lb-trans"><p>诺瓦瓦克斯最近的组织变动和与武田的合作修订可能会增强公司的未来收入来源和运营灵活性。在这些公告后，股价上涨 13% 表明投资者信心上升。然而，从长远来看，考虑到股价变动和股息，公司总回报在过去一年中下降了 48.27%。这一时期突显了诺瓦瓦克斯面临的重大波动性和挑战，强调了持续战略调整的必要性。</p>
</div><p>Compared to the broader market, which rose 11.9%, and the U.S. Biotechs industry, which experienced a 14.2% decline over the past year, Novavax's shares have underperformed significantly. Analyst forecasts indicate revenue is expected to decline 31% annually over the next three years, with earnings projected to decrease 44.3% annually. The recent announcements might help mitigate some of these declines by potentially expanding market opportunities and enhancing profitability through partnerships, but the ongoing dependency on partner execution remains a major risk.</p>
<div class="lb-trans"><p>与整体市场上涨 11.9% 和美国生物技术行业在过去一年中下降 14.2% 相比，诺瓦瓦克斯的股票表现显著不佳。分析师预测，未来三年收入预计将每年下降 31%，而收益预计将每年下降 44.3%。最近的公告可能有助于缓解部分下降，通过潜在扩大市场机会和通过合作伙伴关系增强盈利能力，但对合作伙伴执行的持续依赖仍然是一个主要风险。</p>
</div><p>The price target set by analysts is US$15.17, notably higher than the current share price of US$6.42. This implies substantial growth potential if Novavax can meet future expectations. The company's continued adaptation through partnerships and cost optimization efforts are critical elements that could influence its revenue and earnings growth perspectives, moving closer to the analysts' valuation expectations.</p>
<div class="lb-trans"><p>分析师设定的目标价为 15.17 美元，显著高于当前股价 6.42 美元。这意味着如果诺瓦瓦克斯能够满足未来预期，潜在增长空间巨大。公司通过合作伙伴关系和成本优化的持续适应是影响其收入和收益增长前景的关键因素，使其更接近分析师的估值预期。</p>
</div><p>Gain insights into Novavax's outlook and expected performance with our report on the company's earnings estimates.</p>
<div class="lb-trans"><p>通过我们的报告获取诺瓦瓦克斯的前景和预期表现的见解。</p>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，性质为一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也不考虑你的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><p>If you're looking to trade Novavax, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.</p>
<div class="lb-trans"><p>如果你想交易诺瓦瓦克斯，请在专业人士信任的最低成本平台 Interactive Brokers 开设账户。</p>
</div><p>With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.</p>
<div class="lb-trans"><p>IBKR 在 200 多个国家和地区拥有客户，并可访问 160 个市场，让你可以通过一个集成账户交易股票、期权、期货、外汇、债券和基金。</p>
</div><p>Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.</p>
<div class="lb-trans"><p>享受无隐藏费用、无账户最低限额，外汇转换率低至 0.03%，远优于大多数经纪商提供的服务。</p>
</div><p>Sponsored Content</p>
<div class="lb-trans"><p>赞助内容</p>
</div>

诺瓦瓦克斯医药（NasdaqGS:NVAX）公布 2025 年第一季度财务状况好转